Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

NICE seeks to reduce patient harm from known drug allergy

  • Comment

The National Institute for Health and Care Excellence has published draft guidance aimed at addressing confusion over the clinical management of people affected by drug allergy.

Almost one million patients admitted to NHS hospitals each year are allergic to a drug, with penicillin being most common.

However, around 80% of patient safety incidents involving a drug allergy occur in patients with a known drug allergy, according to NICE.

The institute warned that many of these known allergies were missed because staff failed to take note of clinical charts or allergy bracelets, or simply did not ask the patient about possible allergies.

“A fifth of patients with a known allergy will suffer serious harm”

Mark Baker

The draft recommendations provide best practice advice for healthcare professionals at all levels on diagnosis, documentation and communication of drug allergy in adults, young people and children.

They highlight the importance of referring certain people labelled with a drug allergy to confirm or exclude their status and, if they have a confirmed drug allergy, to find out what alternative treatment can be taken safely.

Professor Mark Baker, director of the Centre for Clinical Practice at NICE, said: “Hospital admissions for drug allergies are increasing and unfortunately over a fifth of patients with a known allergy will suffer serious harm, or in a small number of cases may even die, because they were given that drug again.

“This draft guidance urges all healthcare professionals to be alert to the possibility of allergies when administering drugs and provides recommendations on how to properly take heed of them, so that people can be spared from further harm,” he said.

He added: “We now urge all registered stakeholders for this guidance to submit their comments on our draft recommendations.”

The public consultation on the draft guideline closes on 16 May. The final guideline is expected to be published in September.


  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.